Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
NCT05083182 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG Guselkumab
Study Locations (20)
Other
- STAT Research S A — Ciudad Autonoma Buenos Aires
- Hospital de Ninos de Cordoba — Córdoba
- Instituto Medico Platense — La Plata
- Instituto Caici — Rosario
- Centro Medico Privado de Reumatologia — San Miguel de Tucumán
- Aarhus Universitetshospital — Aarhus
- Odense Universitets Hospital — Odense
- CHU de Caen — Caen
- Hopital de Bicetre — Le Kremlin-Bicêtre
- Hopital Nord Marseille — Marseille
- CHU de Toulouse Hopital des Enfants — Toulouse
California
- Childrens Hospital Los Angeles — Los Angeles
- UCLA — Los Angeles
New York
- Northwell Health — New York
- Montefiore Medical Center — The Bronx
Massachusetts
- Harvard Medical School - Boston Children's Hospital — Boston
North Carolina
- University of North Carolina — Chapel Hill
Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati
Oregon
- Legacy Emanuel Medical Center — Portland
Utah
- University of Utah — Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2026-12-05 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05083182
The ClinicalTrials.gov registry entry for NCT05083182 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 442 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Arthritis, Juvenile appearing as the primary indexed condition, and to 2 interventions — of which Ustekinumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05083182 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Other, California, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05083182 about?
NCT05083182 is a clinical study titled "A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis". The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
What is the current status of trial NCT05083182?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2022-08-30. Estimated completion is 2026-12-05.
What conditions does trial NCT05083182 study?
This clinical trial studies the following conditions: Arthritis, Juvenile. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05083182?
The interventions under investigation include: Ustekinumab (DRUG), Guselkumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05083182?
This trial is sponsored by Janssen Research & Development, which has 442 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05083182 being conducted?
This trial has 20 study locations across California, Massachusetts, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.